Diffuse Lung Disease
-
Updates in evidence for rituximab in interstitial lung disease
Interstitial lung diseases (ILD) are a heterogeneous group of fibro-inflammatory disorders that can be progressive despite available therapies. The cornerstones of pharmacologic therapy include immunosuppression and antifibrotics. Data on the […]
-
CHEST grant winners to study health inequities related to air pollution, medication nonadherence, and more
In 2023, CHEST awarded $300,000 in clinical research and community impact grants to 15 individuals. Grant recipients are recognized for their scientifically meritorious achievements, with rigorous metrics to track their […]
-
Gen Z is hooked on vaping
Pulmonologist Evan Stepp, MD, FCCP, has a teenage daughter who doesn’t smoke or vape – as far as he knows, Stepp will admit – but the statistics on youth smoking […]
-
ILD: Time lost is lung lost
First launched in 2022 in partnership with Three Lakes Foundation, Bridging Specialties™: Timely Diagnosis for ILD is a collaborative initiative hinged on bringing together pulmonary and primary care experts. To […]
-
Use of 6-minute walk distance as a clinical trial outcome in interstitial lung disease
Pulmonary arterial hypertension (PH) and more recently interstitial lung disease (ILD) trials use the 6-minute walk test (6MWT) as a primary outcome due to its ability to conveniently capture a […]
-
Increasing primary care doctors’ knowledge of IPF could speed up diagnoses, suggests white paper
Prompt diagnosis of idiopathic pulmonary fibrosis is essential to reduce mortality, and improving education of primary care providers can help, suggests a new white paper. The nonspecific nature of the […]
-
ILD on the rise: Doctors offer tips for diagnosing deadly disease
Too often, when patients come to see Tejaswini Kulkarni, MD, with shortness of breath and cough and are diagnosed with interstitial lung disease (ILD), they are past the point when […]